Published in Mol Cell Biochem on April 06, 2017
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (2001) 23.42
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet (1995) 17.27
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol (2003) 10.10
Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med (2007) 7.69
Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol (2006) 5.68
Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem (2002) 5.61
ER tubules mark sites of mitochondrial division. Science (2011) 5.45
Homocysteine and vascular disease. Lancet (1999) 5.24
The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol (2009) 5.21
Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA (1993) 5.21
The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet (1985) 4.60
The mitochondrial protein hFis1 regulates mitochondrial fission in mammalian cells through an interaction with the dynamin-like protein DLP1. Mol Cell Biol (2003) 4.56
Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. J Cell Biol (2010) 3.91
Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ (2003) 3.75
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation (2010) 3.72
PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science (2013) 3.60
The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol (2013) 3.59
Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol (2005) 3.22
Endothelial dysfunction. J Am Soc Nephrol (2004) 3.18
Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension (2001) 3.04
Emerging functions of mammalian mitochondrial fusion and fission. Hum Mol Genet (2005) 2.84
Cytokines and T-cell homeostasis. Curr Opin Immunol (2007) 2.58
Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet (1988) 2.35
APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest (2007) 2.28
Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci U S A (2006) 2.19
High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest (1994) 2.13
Endothelial mitochondria: contributing to vascular function and disease. Circ Res (2007) 2.11
Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens (2005) 2.09
TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther (2010) 2.01
Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension (2008) 2.00
Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation (2011) 1.95
Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation (2008) 1.91
Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension (2006) 1.91
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res (2012) 1.81
Mitochondrial OPA1, apoptosis, and heart failure. Cardiovasc Res (2009) 1.79
Inflammation, immunity, and hypertensive end-organ damage. Circ Res (2015) 1.77
Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res (2014) 1.69
Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation (2010) 1.68
Structural biology of the Toll-like receptor family. Annu Rev Biochem (2011) 1.66
Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med (1997) 1.65
Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovasc Res (2007) 1.63
Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension (2000) 1.63
Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol (2009) 1.58
Toll-like receptor signaling pathways. Front Immunol (2014) 1.58
The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr (2006) 1.52
Homocysteinemia due to folate deficiency. Metabolism (1987) 1.51
Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med (2006) 1.49
Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol (2014) 1.48
Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr (1999) 1.44
Endothelial cytosolic proteins bind to the 3' untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. Mol Cell Biol (1997) 1.44
Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem (2008) 1.41
Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol (2000) 1.40
The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol (2012) 1.37
Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2002) 1.37
Apoptotic cell death in atherosclerosis. Curr Opin Lipidol (2003) 1.35
Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ (2005) 1.34
Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res (2005) 1.30
Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension (2001) 1.28
Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol (1997) 1.26
High glucose disrupts mitochondrial morphology in retinal endothelial cells: implications for diabetic retinopathy. Am J Pathol (2010) 1.24
Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond) (2012) 1.23
Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J (2004) 1.20
Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res (2012) 1.18
Vascular smooth muscle cell migration: current research and clinical implications. Vasc Endovascular Surg (2004) 1.17
Global DNA methylation patterns in placenta and its association with maternal hypertension in pre-eclampsia. DNA Cell Biol (2010) 1.17
Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal (2011) 1.16
Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int (1997) 1.15
Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol (2001) 1.15
Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem (2006) 1.14
Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics. Am J Physiol Heart Circ Physiol (2013) 1.12
Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA (2004) 1.12
Remethylation defects: guidelines for clinical diagnosis and treatment. Eur J Pediatr (1998) 1.11
Central role of mitofusin 2 in autophagosome-lysosome fusion in cardiomyocytes. J Biol Chem (2012) 1.10
Sensitization of human aortic endothelial cells to lipopolysaccharide via regulation of Toll-like receptor 4 by bacterial fimbria-dependent invasion. Infect Immun (2005) 1.10
Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol (2013) 1.08
Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res (2011) 1.08
Smoothelin in vascular smooth muscle cells. Trends Cardiovasc Med (2007) 1.04
Differing caspase-1 activation states in monocyte versus macrophage models of IL-1beta processing and release. J Leukoc Biol (2004) 1.04
Small artery remodeling: current concepts and questions. J Vasc Res (2009) 1.04
Hemodynamic forces, vascular oxidative stress, and regulation of BMP-2/4 expression. Antioxid Redox Signal (2009) 1.02
Hyperhomocysteinemia and atherosclerosis. Sheng Li Xue Bao (2005) 1.01
Epigenetics and arterial hypertension: the challenge of emerging evidence. Transl Res (2014) 1.01
Homocysteine-mediated modulation of mitochondrial dynamics in retinal ganglion cells. Invest Ophthalmol Vis Sci (2011) 0.99
Vascular wall extracellular matrix proteins and vascular diseases. Biochim Biophys Acta (2014) 0.99
Mechanisms of triglyceride accumulation in activated macrophages. J Leukoc Biol (2012) 0.98
Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J (2004) 0.98
Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J Hum Hypertens (2005) 0.98
Hypertension in pregnancy is associated with elevated homocysteine levels later in life. Am J Obstet Gynecol (2013) 0.98
Vitamin B12 protects against superoxide-induced cell injury in human aortic endothelial cells. Free Radic Biol Med (2011) 0.97
Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. J Innate Immun (2010) 0.97
Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J (2009) 0.97
Increased superoxide anion production by interleukin-1beta impairs nitric oxide-mediated relaxation in resistance arteries. J Pharmacol Exp Ther (2005) 0.96
Mitochondrial function in vascular endothelial cell in diabetes. J Smooth Muscle Res (2012) 0.96
Homocysteine enhances apoptosis in human bone marrow stromal cells. Bone (2006) 0.95
Homocysteine induces monocyte chemoattractant protein-1 expression by activating NF-kappaB in THP-1 macrophages. Am J Physiol Heart Circ Physiol (2001) 0.94
Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role? PPAR Res (2010) 0.94
TNF-alpha induces a decrease in eNOS promoter activity. Am J Physiol Lung Cell Mol Physiol (2003) 0.94
Regulatory role of mitochondria in oxidative stress and atherosclerosis. World J Cardiol (2010) 0.94
Effects of homocysteine on proliferation, necrosis, and apoptosis of vascular smooth muscle cells in culture and influence of folic acid. Thromb Res (2001) 0.94